Immix Biopharma Investor Presentation Deck

IMX-110 Clinical Data: 4-month mPFS in Late Stage Sarcoma, Well Tolerated IMX-110 Median Progression Free Survival in Late Stage STS mPFS (months) 5 4 months 3 2 1 0 0% (note: IMMIX n=4) 20% 40% 60% IMMIX ¡MX-110 4 month mPFS across 100% heavily pre-treated soft tissue sarcoma patients 80% % Of Patients With ≥ 3 Lines Of Treatment Prior to Therapy 100% STS Sub-Indication Leiomyosarcoma Liposarcoma Undifferentiated Pleomorphic Sarcoma ImmixBio iMX-110 Clinical Trial Disease Control @ 2 mos Median Progression Free Survival Dose Interruptions due to Toxicity Drug-Related SAEs Overall Response Rate Median 7th Line (4-14th Line) IMMIX iMX-110 100% 4 months 0% 0% 0% iMX-110 (ImmixBio Unpublished) ●●● IMMIX S BIOPHARMA 14th Line Patient IMMIX ¡MX-110 100% 6 months 0% 0% 0% ¡MX-110 (ImmixBio Unpublished) 54

View entire presentation